New cocktail shows promise for tough lung cancer
NCT ID NCT03575793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs—nivolumab, ipilimumab, and plinabulin—in 39 adults with recurrent small cell lung cancer that had worsened after initial chemotherapy. The goal was to find the safest dose and see if the combo could slow cancer growth. Results from this completed early-phase trial help guide future research, but the treatment is not yet proven to work for everyone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, ipilimumab, and plinabulin
What this could lead to
If this combination works, it could offer a new treatment option for people with recurrent small cell lung cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 39 participants, so results may not apply to everyone. The drugs can cause serious immune-related side effects, and the benefit over existing treatments is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Erlanger Health System
Chattanooga, Tennessee, 37403, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States